Revolutionizing Sepsis Management: Nu.Q® NETs H3.1 Proves Its Worth in Large-Scale Study

In a groundbreaking development, VolitionRx Limited (NYSE AMERICAN: VNRX) has announced significant results from a large-scale study of its Nu.Q® NETs H3.1 biomarker in sepsis patients. The study, analyzing plasma samples from 971 patients with sepsis and septic shock, demonstrates that the biomarker can independently predict 28-day mortality and the need for renal replacement therapy (RRT). This marks a significant milestone for Volition's Nu.Q® NETs H3.1 biomarker, as it shows potential for risk stratification and early intervention in critically ill sepsis patients.

The study, published in a paper currently undergoing peer review and accessible on MEDRXIV, shows that Nu.Q® NETs H3.1 is a promising novel biomarker for early mortality and organ dysfunction in sepsis. The biomarker's levels were significantly higher in septic shock patients compared to sepsis patients, indicating a clear dose-response relationship with acute kidney injury severity. This suggests that Nu.Q® NETs H3.1 could be used to identify high-risk patients early, enabling more aggressive interventions and closer monitoring.



The study's strengths are particularly noteworthy. It is multi-centered, randomized, and prospective, providing robust Level 1 evidence. The biomarker shows a clear dose-response relationship with acute kidney injury severity, which is essential for clinical validity. Moreover, the independence from conventional markers suggests that Nu.Q® NETs H3.1 provides unique, complementary information to existing diagnostic tools.

From a clinical utility perspective, early risk stratification in sepsis is crucial as mortality rates increase significantly with delayed intervention. Current sepsis biomarkers have limitations in predicting outcomes and organ dysfunction. Nu.Q® NETs' ability to identify high-risk patients early could enable more aggressive interventions and closer monitoring of at-risk individuals, potentially improving patient survival and quality of life.

The commercial implications of these findings are substantial. The global sepsis diagnostics market is projected to reach several billion dollars, and there's a critical need for better prognostic tools. Volition's mention of 'active commercial discussions with significant players' suggests potential licensing deals or partnerships could be forthcoming. The test's described attributes - simple, low-cost, and accessible - align well with market demands for point-of-care diagnostics.



In conclusion, VolitionRx Limited's Nu.Q® NETs H3.1 biomarker has shown great promise in predicting 28-day mortality and the need for renal replacement therapy in sepsis patients. With its simplicity, cost-effectiveness, and accessibility, the Nu.Q® NETs H3.1 test aligns well with market demands for point-of-care diagnostics in sepsis. As Volition continues to engage in commercial discussions with major diagnostic industry players, the future of sepsis management looks more hopeful than ever.